<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To describe the ocular effects associated with the administration of the systemic epidermal growth factor receptor (EGFR) inhibitors panitumumab and <z:chebi fb="0" ids="114785">erlotinib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Retrospective, noncomparative interventional case series </plain></SENT>
<SENT sid="2" pm="."><plain>PARTICIPANTS: Ten eyes of 5 patients in treatment with systemic EGFR inhibitors, 4 patients with <z:chebi fb="0" ids="114785">erlotinib</z:chebi> for end-stage <z:mp ids='MP_0008714'>lung carcinoma</z:mp>, and 1 patient with panitumumab for end-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Data collected from charts included gender, age at presentation, <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e>, and clinical presentation in each eye </plain></SENT>
<SENT sid="4" pm="."><plain>MAIN OUTCOME MEASURES: Demographics on presentation and clinical findings </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Multiple epithelial defects were observed in <z:hpo ids='HP_0000001'>all</z:hpo> 10 eyes, corneal melting and thinning were observed in 3 eyes of 2 patients, 2 eyes of 1 patient presented with lower lid <z:hpo ids='HP_0000656'>ectropion</z:hpo>, and 2 eyes of 2 patients presented with <z:hpo ids='HP_0100583'>corneal perforation</z:hpo>, both requiring a penetrating keratoplasty </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Severe ocular side effects, including <z:hpo ids='HP_0100583'>corneal perforation</z:hpo>, may be associated with the use of the EGFR inhibitors panitumumab and <z:chebi fb="0" ids="114785">erlotinib</z:chebi> </plain></SENT>
</text></document>